Nuvation Bio Inc (NUVB) - Net Assets
Based on the latest financial reports, Nuvation Bio Inc (NUVB) has net assets worth $319.56 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($610.24 Million) and total liabilities ($290.68 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Nuvation Bio Inc tangible book value ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $319.56 Million |
| % of Total Assets | 52.37% |
| Annual Growth Rate | N/A |
| 5-Year Change | -59.02% |
| 10-Year Change | N/A |
| Growth Volatility | 99.22 |
Nuvation Bio Inc - Net Assets Trend (2018–2025)
This chart illustrates how Nuvation Bio Inc's net assets have evolved over time, based on quarterly financial data. See Nuvation Bio Inc liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Nuvation Bio Inc (2018–2025)
The table below shows the annual net assets of Nuvation Bio Inc from 2018 to 2025. For live valuation and market cap data, see NUVB market cap overview.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $305.72 Million | -34.08% |
| 2024-12-31 | $463.79 Million | -23.36% |
| 2023-12-31 | $605.12 Million | -7.63% |
| 2022-12-31 | $655.08 Million | -12.19% |
| 2021-12-31 | $746.00 Million | +246.84% |
| 2020-12-31 | $215.08 Million | +82.66% |
| 2019-12-31 | $117.75 Million | +15926.34% |
| 2018-12-31 | $-744.00K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Nuvation Bio Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 111462600000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $1.42 Billion | 464.90% |
| Other Comprehensive Income | $-187.00K | -0.06% |
| Total Equity | $305.72 Million | 100.00% |
Nuvation Bio Inc Competitors by Market Cap
The table below lists competitors of Nuvation Bio Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Coty Inc
NYSE:COTY
|
$1.72 Billion |
|
Bob's Discount Furniture, Inc.
NYSE:BOBS
|
$1.72 Billion |
|
Jiangsu Gian Technology Co Ltd
SHE:300709
|
$1.72 Billion |
|
Atrium Ljungberg AB (publ)
ST:ATRLJ-B
|
$1.72 Billion |
|
Grupo Gigante S. A. B. de C. V
MX:GIGANTE
|
$1.72 Billion |
|
Faraday Technology Corp
TW:3035
|
$1.72 Billion |
|
SÜSS MicroTec SE
F:SMHN
|
$1.72 Billion |
|
Montana Aerospace AG
SW:AERO
|
$1.72 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Nuvation Bio Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 463,788,000 to 305,716,000, a change of -158,072,000 (-34.1%).
- Net loss of 204,627,000 reduced equity.
- Other comprehensive income decreased equity by 760,000.
- Other factors increased equity by 47,315,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-204.63 Million | -66.93% |
| Other Comprehensive Income | $-760.00K | -0.25% |
| Other Changes | $47.31 Million | +15.48% |
| Total Change | $- | -34.08% |
Book Value vs Market Value Analysis
This analysis compares Nuvation Bio Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 6.21x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-12-31 | $0.00 | $5.56 | x |
| 2019-12-31 | $0.57 | $5.56 | x |
| 2020-12-31 | $0.99 | $5.56 | x |
| 2021-12-31 | $3.77 | $5.56 | x |
| 2022-12-31 | $3.02 | $5.56 | x |
| 2023-12-31 | $2.76 | $5.56 | x |
| 2024-12-31 | $1.73 | $5.56 | x |
| 2025-12-31 | $0.90 | $5.56 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Nuvation Bio Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -66.93%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -325.31%
- • Asset Turnover: 0.11x
- • Equity Multiplier: 1.95x
- Recent ROE (-66.93%) is below the historical average (-34.67%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | 0.00% | 0.00% | 0.00x | 0.00x | $-917.60K |
| 2019 | -28.49% | 0.00% | 0.00x | 1.03x | $-45.33 Million |
| 2020 | -19.37% | 0.00% | 0.00x | 1.03x | $-63.17 Million |
| 2021 | -11.64% | 0.00% | 0.00x | 1.04x | $-161.45 Million |
| 2022 | -15.91% | 0.00% | 0.00x | 1.03x | $-169.71 Million |
| 2023 | -12.53% | 0.00% | 0.00x | 1.03x | $-136.31 Million |
| 2024 | -122.46% | -7213.76% | 0.01x | 1.17x | $-614.32 Million |
| 2025 | -66.93% | -325.31% | 0.11x | 1.95x | $-235.20 Million |
Industry Comparison
This section compares Nuvation Bio Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $131,878,234
- Average return on equity (ROE) among peers: -44.16%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Nuvation Bio Inc (NUVB) | $319.56 Million | 0.00% | 0.91x | $1.72 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $85.57 Million |
| Abcellera Biologics Inc (ABCL) | $830.51 Million | 14.32% | 0.21x | $1.61 Billion |
| Abeona Therapeutics Inc (ABEO) | $1.69 Million | 20.23% | 0.26x | $328.21 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $-18.59 Million | 0.00% | 0.00x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $-12.35 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $274.41 Million | -38.23% | 0.17x | $1.01 Billion |
| Arbutus Biopharma Corp (ABUS) | $203.00 Million | -189.21% | 0.36x | $831.63 Million |
| ABVC Biopharma Inc (ABVC) | $8.87 Million | -144.74% | 0.54x | $35.10 Million |
| Abivax SA American Depositary Shares (ABVX) | $48.18 Million | -23.29% | 0.12x | $7.90 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $17.86 Million | -80.65% | 0.23x | $3.66 Billion |
About Nuvation Bio Inc
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. The company's lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. It is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 3 clinical trials for the ma… Read more